



Republic of the Philippines
Department of Health
FOOD AND DRUG ADMINISTRATION



09 June 2015

FDA ADVISORY
No. 2015-037

SUBJECT: Public Health Warning Against the Use of the Following Unregistered Drug Products:

1. **Metformin Hydrochloride 0.5 g Sustained-Release Tablets, Marketing Authorization Holder: Youcare Pharmaceutical Group Co., Ltd.**
2. **Doxazosin Mesylate 2 mg Tablets, Marketing Authorization Holder: In Foreign Language**
3. **Ibuprofen 0.75 g/ 15 g Gel, Marketing Authorization Holder: In Foreign Language**
4. **Terbinafine Hydrochloride 10 mg/ 10 g Gel, Marketing Authorization Holder: In Foreign Language**
5. **3d+ Weight Reduction 250 mg Capsule**
6. **Jianergang Capsule**
7. **Dragon Power for Men Capsule**

The Food and Drug Administration advises the public against the use of the following unregistered drug products:

Metformin Hydrochloride Sustained-release Tablets
[Component] The main component of this product is Metformin Hydrochloride. Please see the details in the leaflet.
[Description] This product is a white to off white tablets or film coated tablets, and show white to off white after coating removed.
[Indications] Suitable for patients with type II diabetes which cannot get good control with diet and exercise. This product can be used alone, and also be combined with sulfonylurea or insulin.
[Strength] 0.5g
[Usage and Dosage] Orally, during or after meal. The initial dosage usually is 1 tablet each time (0.5g), once a day when taking dinner, adjusting dosage according to the blood glucose and urine glucose, and the maximum daily dose should not exceed four tablets (2g). If once a day, four tablets each time (2g) can not achieve satisfactory curative effect, it can be changed to twice a day, two tablets each time (1g).
[Validity] 24 months
[Adverse Reactions] [Contraindications] [Precautions] Please see the details in the leaflet.
[Storage] Be airtight and stored in a cool and dry place at a temperature not above 20 °C.
[Packing] Aluminum-plastic blister packing: 10 tablets/blister*3blisters/box

METFORMIN HYDROCHLORIDE 0.5 g SUSTAINED-RELEASE TABLETS
Marketing Authorization Holder: Youcare Pharmaceutical Group Co., Ltd.





DOXAZOSIN MESYLATE 2 mg TABLETS

Marketing Authorization Holder: In Foreign Language



IBUPROFEN 0.75 g/ 15 g GEL

Marketing Authorization Holder: In Foreign Language



TERBINAFINE HYDROCHLORIDE 10 mg/ 10 g GEL
 Marketing Authorization Holder: In Foreign Language



3d+ WEIGHT REDUCTION 250 mg CAPSULE
 Sole Agent: Hong Kong Shou Zhi Su Technology Development Centre



JIANER GANG CAPSULE
Sole Agent: Lovetonic (France) Co., Ltd.



DRAGON POWER FOR MEN CAPSULE
Sole Agent: Lovetonic (France) Co., Ltd.

Table 1. Unregistered Drug Products

The abovementioned drug products pose potential danger or injury to the consuming public and the importation, selling or offering for sale of such is in direct violation of Republic Act No. 9711 or the Food and Drug Administration Act of 2009.


In the interest of protecting public health and safety, and pursuant to Section 12 of R.A. No. 9711, the Field Regulatory Operations Office (FROO) Officers of this Office are hereby ordered to seize the aforementioned unregistered drug products found in the market.

All establishments and outlets are hereby warned against selling and/or dispensing the above identified products. Anyone found selling the said products will be penalized.

Likewise, all local government units and law enforcement agencies are requested to ensure that these products are not sold or offered for sale in their localities or area of jurisdiction.

All consumers are advised to purchase their medications only from FDA-licensed establishments. Please note that in addition to inspection of establishments, product evaluation, registration and testing are measures that the government undertakes to ensure the quality, safety and efficacy of health products. Please look for the FDA Registration number on the product label. Moreover, please be reminded that drug products registered with FDA Philippines bear in their labels information in English and/or in Filipino for all consumers to understand.

For more information and inquiries, please email us at info@fda.gov.ph. To report continuous sale or distribution of unregistered health products, kindly email us via report@fda.gov.ph or you may call the telephone number (02)807-8275. For any suspected adverse drug reaction (ADR), report immediately to FDA through this link: www.fda.gov.ph/adr-report-new and fill out all the required fields.


JANETTE P. LORETO-GARIN, MD, MBA-H
Secretary of Health
Acting Director General¹

DTN:20150521093433

¹ Pursuant to DPO 2015-1845